Tigermed announced that the company plans to acquire a total of 40.5650% equity of Genor Biopharma held by Dian Diagnostics and Suzhou Yingkai in cash, with a total purchase price of RMB 0.14 billion. After the transaction is completed, the company will directly and indirectly hold 72.8169% equity of Genor Biopharma, which will be included in the company's consolidated financial statements.
泰格医药：拟1.4亿元收购观合医药40.5650%股权
Tigermed: intends to acquire 40.5650% equity of Quanhe Pharmaceutical for 0.14 billion yuan.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated